The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Recurrence-free survival as a surrogate for overall survival in esophageal squamous cell carcinoma: Nationwide real-world data from Japan.
 
Jun Okui
No Relationships to Disclose
 
Kengo Nagashima
Consulting or Advisory Role - Kowa; Senju Pharmaceutical; Toray Industries
 
Satoru Matsuda
Speakers' Bureau - Bristol-Myers Squibb; Daiichi Sankyo; MSD; Novartis; Olympus; Ono Pharmaceutical
 
Yasunori Sato
Honoraria - Eisai
Consulting or Advisory Role - Mochida Pharmaceutical Co. Ltd.
 
Akihiko Okamura
No Relationships to Disclose
 
Hirofumi Kawakubo
No Relationships to Disclose
 
Manabu Muto
Speakers' Bureau - Canon Medical System; Chugai Pharma; Daiichi Sankyo/Lilly; Illumina; Incyte Japan; Merck; MSD; Novartis; Olympus; Ono Pharmaceutical; Shionogi
Research Funding - Canon Medical System; Chugai Pharma; H.U. Group Holdings; Meiji Seika Kaisha; NTT; NTT Data; Taiho Pharmaceutical
 
Yoshihiro Kakeji
Honoraria - Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Takeda; Tsumura & Co.
Research Funding - Chugai Pharma (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Koji Kono
Speakers' Bureau - Bristol-Myers Squibb Japan; MSD Oncology; Ono Pharmaceutical; Taiho Pharmaceutical
 
Hiroya Takeuchi
Honoraria - Abbott Japan; Bristol-Myers Squibb Japan; Daiichi Sankyo/Astra Zeneca; EA Pharma; Hisamitsu Pharmaceutical; Intuitive Surgical; Johnson & Johnson/MedTech; Kaken Pharmaceutical; Medicon; Medtronic; Miyarisan pharmaceutical; MSD K.K; Nichiiko K.K.; Ono Pharmaceutical; Otsuka; Otsuka; Taiho Pharmaceutical; Tsumura & Co.
Research Funding - Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Johnson & Johnson/MedTech; Kaken Pharmaceutical; Kyowa Hakko Kirin K. K.; Lilly Japan; Otsuka; Taiho Pharmaceutical
 
Masayuki Watanabe
No Relationships to Disclose
 
Yuichiro Doki
Honoraria - Chugai Pharma; Daiichi Sankyo; Lilly Japan; MSD; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical
Consulting or Advisory Role - Ono Pharmaceutical
Research Funding - Chugai Pharma; Daiichi Sankyo; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
 
Takeo Bamba
No Relationships to Disclose
 
Takashi Fukuda
No Relationships to Disclose
 
Hitoshi Fujiwara
No Relationships to Disclose
 
Shinsuke Sato
No Relationships to Disclose
 
Kazuhiro Noma
No Relationships to Disclose
 
Hiroshi Miyata
No Relationships to Disclose
 
Takeo Fujita
No Relationships to Disclose
 
Yuko Kitagawa
Honoraria - Asahi Kasei; ASKA Pharmaceutical Co., Ltd.; AstraZeneca Japan; Bristol-Myers Squibb K.K.; Chugai Foundation for Innovative Drug Discovery Science; Chugai Pharma; DAIICHI SANKYO COMPANY, LIMITED; EA Pharma; Ethicon; Intuitive Surgical; Kaken Pharmaceutical; Miyarisan pharmaceutical; MSD K.K.; Nippon Covidien; Nippon Kayaku; Olympus; Ono Pharmaceutical; Otsuka; Shionogi; Smith & Nephew; Sysmex; Taiho Pharmaceutical; Toray Industries
Consulting or Advisory Role - Bristol-Myers Squibb K.K.; Ono Pharmaceutical
Research Funding - Asahi Kasei (Inst); Chugai Pharma (Inst); Eisai (Inst); Kaken Pharmaceutical (Inst); Kowa (Inst); Kyouwa Hakkou Kirin Co., Ltd. (Inst); Nippon Covidien (Inst); Otsuka (Inst); Otsuka (Inst); Sumitomo Pharma Co., Ltd. (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Teijin Pharma (Inst); TSUMURA & CO. (Inst)